Real World Treatment Data for Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Darcy Trimpe, PhD, U.S. Medical Director at Amgen, discusses real world data on Tavneos (avacopan) for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

GPA is a type of vasculitis of the blood vessels. The disease can affect any part of the body but mainly impacts the sinuses, nose, trachea, lungs, and kidneys. The swelling can limit the flow of blood to these body parts, causing damage. Symptoms of the disease can include sinus pain, recurrent respiratory infections, joint pain, fatigue, and skin lesions. The exact cause of GPA is unknown, but it is a type of autoimmune disease.

MPA is a type of vasculitis which can lead to organ damage. The kidneys, lungs, nerves, skin, and joints are the most commonly affected areas of the body. The cause of this disorder is unknown.

Avacopan is a complement 5a receptor (C5aR) antagonist that blocks the complement-mediated cycle of chronic inflammation. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with severe active GPA or MPA.

80 patients were analyzed as part of an ongoing retrospective study, with 67 of these patients initiating avacopan. Complete remission (CR) in this study is defined as Birmingham Vasculitis Activity Score (BVAS) equaling zero at month six and no glucocorticoids (GC) after month five. At month 6 median GC dose was 1,0111mg (n=67), 82% had BVAS equaling zero, and 66% achieved CR. Overall, most participants discontinued GC by the fifth month and had achieved CR and demonstrated favorable renal outcomes.